Monogenic disorders of the pancreatic β-cell: Personalizing treatment for rare forms of diabetes and hypoglycemia

Personalized Medicine

Volumn 4, Issue 3, 2007, Pages 247-259

  van de Bunt, Martijn ^a   Gloyn, Anna L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Diabetes; Hyperinsulinemia; Insulin; Maturity onset diabetes of the young; Monogenic; Neonatal diabetes; Pharmacogenetics; Sulfonylureas

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 6 FLUORODOPA F 18; ABC TRANSPORTER; ABC TRANSPORTER C8; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; DIAZOXIDE; GLICLAZIDE; GLUCOKINASE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 4; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HEPATOCYTE NUCLEAR FACTOR 4BETA; INSULIN; METFORMIN; NEUROGENIC DIFFERENTIATION FACTOR; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCNJ11; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; UNCLASSIFIED DRUG;

BIRTH WEIGHT; CHROMOSOME 6Q; CLINICAL TRIAL; DIABETES MELLITUS; DIET THERAPY; DIFFERENTIAL DIAGNOSIS; DRUG MEGADOSE; GENE MUTATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GLYCEMIC CONTROL; HOMOZYGOSITY; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; LOW DRUG DOSE; MATURITY ONSET DIABETES MELLITUS; MONOGENIC DISORDER; NEWBORN DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS RESECTION; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 34548395112     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.4.3.247     Document Type: Review

References (121)

1. Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature 414, 782-787 (2001).
2. Pearson ER, Liddell WG, Shepherd M, Corrall RJ, Hattersley AT: Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor 1α gene mutations: evidence for pharmacogenetics in diabetes. Diabet. Med. 17, 543-545 (2000).
3. Pearson ER, Starkey EJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT: Genetic aetiology of hyperglycaemia determines response to treatment in diabetes. Lancet 362, 1275-1281 (2003).
4. Sagen JV, Ræder H, Hathout E et al.: Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes 53, 2713-2718 (2004).
5. Klupa T, Edghill EL, Nazim J et al.: The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of β-cell function among carriers of the R201H mutation. Diabetologia 48, 1029-1031 (2005).
6. Codner E, Flanagan S, Ellard S, Garcia H, Hattersley AT: High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation. Diabetes Care 28, 758-759 (2005).
7. Pearson ER, Flechtner I, Njolstad PR et al.: Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N. Engl. J. Med. 355, 467-477 (2006).
8. Owen KR, Stride A, Ellard S, Hattersley AT: Etiological investigation of diabetes in young idults presenting with apparent Type 2 diabetes. Diabetes Care 26, 2088-2093 (2003).
9. Edghill EL, Dix RJ, Flanagan SE et al.: HLA genotyping supports a nonautoimmune etiology in patients diagnosed with diabetes under the age of 6 months. Diabetes 55, 1895-1898 (2006).
10. Stride A, Hattersley AT: Different genes, different diabetes: lessons from maturity-onset diabetes of the young. Ann. Med. 34, 207-216 (2002).
11. American Diabetes Association: Type 2 diabetes in children and adolescents. Diabetes Care 23, 381-389 (2000).
12. Haines L, Wan KC, Lynn R, Barrett TG, Shield JP: Rising Incidence of type 2 diabetes in children in the U.K. Diabetes Care 30, 1097-1101 (2007).
13. Maassen JA, Janssen GM, t'Hart LM: Molecular mechanisms of mitochondrial diabetes (MIDD). Ann. Med. 37, 213-221 (2005).
14. Shepherd M, Hattersley A, Ellard S: Integration of the MODY link nurse project: 20-month evaluation. J. Diabetes Nurs. 9(2), 47-52 (2005).
15. Tattersall RB: Mild familial diabetes with dominant inheritance. Q. J. Med. 43, 339-357 (1974).
16. Fajans SS, Bell GI, Polonsky KS: Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N. Engl. J. Med. 345, 971-980 (2001).
17. Froguel P, Zouali H, Vionnet N et al.: Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. N. Eng. J. Med. 328, 697-702 (1993).
18. Frayling T, Bulman MP, Ellard S et al.: Mutations in the hepatocyte nuclear factor-1α gene are a common cause of maturity-onset diabetes of the young in the United Kingdom. Diabetes 46, 720-725 (1997).
19. Shield JP, Gardner RJ Wadsworth EJ et al.: Aetiopathology and genetic basis of neonatal diabetes. Arch. Dis. Child. 76, F39-F42 (1997).
20. von Muhlendahl KE, Herkenhoff H: Long-term course of neonatal diabetes. N. Engl. J. Med. 333, 704-708 (1995).
21. Iafusco D, Stazi MA, Cotichini R et al.: Permanent diabetes mellitus in the first year of life. Diabetologia 45, 798-804 (2002).
22. Gloyn AL, Pearson ER, Antcliff JF et al.: Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl. J. Med. 350, 1838-1849 (2004).
23. Babenko AP, Polak M, Cave H et al.: Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N. Engl. J. Med. 355, 456-466 (2006).
24. Proks P, Arnold AL, Bruining J et al.: A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Hum. Mol. Genet. 15, 1793-1800 (2006).
25. Vaxillaire M, Populaire C, Bulsiah K et al.: Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. Diabetes 53, 2719-2722 (2004).
26. Massa O, Iafusco D, D'Amato E et al.: KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes. Hum. Mutat. 25, 22-27 (2004).
27. Temple IK, Gardner RJ, Mackay DJ, Barber JC, Robinson DO, Shield JP: Transient neonatal diabetes: widening the understanding of the etiopathogenesis of diabetes. Diabetes 49, 1359-1366 (2000).
28. ATP-channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. Diabetes (2007) (Epub ahead of print).
29. Glaser B, Thornton PS, Otonkoski T, Junien C: The genetics of neonatal hyperinsulinism. Arch. Dis. Child. 82, 79-86 (2000).
30. Nestorowicz A, Wilson BA, Schoor KP et al.: Mutations in the sulphonylurea gene are associated with familial hyperinsulinism in Ashkenazi Jews. Hum. Mol. Genet. 5, 1813-1822 (1996).
31. Nichols CG, Shyng SL, Newtorowicz A et al.: Adenosine diphosphate as an intracellular regulator of insulin secretion. Science 272, 1785-1787 (1996).
32. Thomas PM, Yuyang Y, Lightner E: Mutation of the pancreatic islet inward rectifier, Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. Hum. Mol. Genet. 15, 1809-1812 (1996).
33. Glaser B, Kesavan P, Haymen M et al.: Familial hyperinsulinism caused by an activating glucokinase mutation. N. Engl. J. Med. 338, 226-230 (1998).
34. Stanley CA, Lieu YK, Hsu BY et al.: Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. N. Engl. J. Med. 338, 1352-1357 (1998).
35. Clayton PT, Eaton S, Aynsley-Green A et al.: Hyperinsulinism in short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency reveals the importance of β-oxidation in insulin secretion. J. Clin. Invest. 108, 457-465 (2001).
36. de Leon DD, Stanley CA: Mechanisms of disease: advances in diagnosis and treatment of hyperinsulinism in neonates. Nat. Clin. Pract. Endocrinol. Metab. 3, 57-68 (2007).
37. Frayling TM, Evans JC, Bulman MP et al.: β-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors. Diabetes 50, S94-S100 (2001).
38. Yamagata K, Oda N, Kaisaki PJ et al.: Mutations in the hepatic nuclear factor-1α gene in maturity-onset diabetes of the young (MODY3). Nature 384, 455-458 (1996).
39. Yamagata K, Furuta H, Oda N et al.: Mutations in the hepatocyte nuclear factor-4α gene in maturity-onset diabetes of the young (MODY1). Nature 384, 458-460 (1996).
40. Ferrer J: A genetic switch in pancreatic β-cells: implications for differentiation and haploinsufficiency. Diabetes 51, 2355-2362 (2002).
41. Pearson ER, Velho G, Clark P et al.: β-cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1α and glucokinase mutations. Diabetes 50, S101-S107 (2001).
42. Pearson E, Boj S, Steele A et al.: Macrosomia, and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med. 4, E118 (2007).
43. Pearson ER, Pruhova S, Tack CJ et al.: Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor-4α mutations in a large European collection. Diabetologia 48, 878-885 (2005).
44. Shepherd M, Pearson ER, Houghton J, Salt G, Ellard S, Hattersley AT: No deterioration in glycemic control in HNF-1α maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas. Diabetes Care 26, 3191-3192 (2003).
45. Shepherd M, Hattersley AT: 'I don't feel like a diabetic any more': the impact of stopping insulin in patients with maturity onset diabetes of the young following genetic testing. Clin. Med. 4, 144-147 (2004).
46. Beards F, Frayling T, Bulman M et al.: Mutations in hepatocyte nuclear factor-1β are not a common cause of maturity-onset diabetes of the young in the U.K. Diabetes 47, 1152-1154 (1998).
47. Horikawa Y, Iwasaki N, Hara M et al.: Mutation in hepatocyte nuclear factor-1β gene (TCF2) associated with MODY. Nature Genet. 17, 384-385 (1997).
48. Edghill EL, Bingham C, Ellard S, Hattersley AT: Mutations in hepatocyte nuclear factor-1β and their related phenotypes. J. Med. Genet. 43, 84-90 (2006).
49. Bingham C, Hattersley AT: Renal cysts and diabetes syndrome resulting from mutations in hepatocyte nuclear factor-1β. Nephrol. Dial. Transplant 19, 2703-2708 (2004).
50. Brackenridge A, Pearson ER, Shojaee-Moradie F, Hattersley AT, Russell-Jones D, Umpleby AM: Contrasting insulin sensitivity of endogenous glucose production rate in subjects with hepatocyte nuclear factor-1β and - 1α mutations. Diabetes 55, 405-411 (2006).
51. Pearson ER, Badman MK, Lockwood CR et al.: Contrasting diabetes phenotypes associated with hepatocyte nuclear factor-1α and -1β mutations. Diabetes Care 27, 1102-1107 (2004).
52. Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF: Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nature Genet. 15, 106-110 (1997).
53. Schwitzgebel VM, Mamin A, Brun T et al.: Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1. J. Clin. Endocrinol. Metab. 88, 4398-4406 (2003).
54. Stoffers DA, Ferrer J, Clarke WL, Habener JF: Early-onset Type-II diabetes mellitus (MODY4) linked to IPF1. Nat. Genet. 17, 138-139 (1997).
55. Chèvre JC, Hani EH, Stoffers A, Habener JF, Froguel P: Insulin promoter factor 1 gene (IPF1) is not a major cause of maturity-onset diabetes of the young in French caucasians. Diabetes 47, 843-844 (1998).
56. Hara M, Lindner TH, Paz VP et al.: Mutations in the coding region of the insulin promoter factor 1 gene are not a common cause of maturity-onset diabetes of the young in Japanese subjects. Diabetes 47, 845-846 (1998).
57. Malecki MT, Jhala US, Antonellis A et al.: Mutations in NEUROD1 are associated with the development of Type 2 diabetes mellitus. Nat. Genet. 23, 323-328 (1999).
58. Kristinsson SY, Thorolfsdottir ET, Talseth B et al.: MODY in Iceland is associated with mutations in HNF-1α and a novel mutation in NeuroD1. Diabetologia 44, 2098-2103 (2001).
59. Matschinsky FM: Regulation of pancreatic β-cell glucokinase: from basics to therapeutics. Diabetes 51(Suppl. 3), S394-S404 (2002).
60. Gloyn AL: Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy. Hum. Mutat. 22, 353-362 (2003).
61. Weedon MN, Qian CV, Ben-Shlomo Y et al.: A common haplotype of the glucokinase gene alters fasting glucose and birth weight: association in six studies and population-genetics analyses. Am. J. Hum. Genet. 79, 991-1001 (2006).
62. Hattersley AT, Turner RC, Permutt MA et al.: Linkage of Type 2 diabetes to the glucokinase gene. Lancet 339, 1307-1310 (1992).
63. Froguel P, Vaxillaire M, Sun F et al.: Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Nature 356, 162-164 (1992).
64. Stride A, Vaxillaire M, Tuomi T et al.: The genetic abnormality in the β cell determines the response to an oral glucose load. Diabetologia 45, 427-435 (2002).
65. Sturis J, Kurland IJ, Byrne MM et al.: Compensation in pancreatic β-cell function in subjects with glucokinase mutations. Diabetes 43, 718-723 (1994).
66. Hattersley AT, Beards F, Ballantyne E, Appleton M, Harvey R, Ellard S: Mutations in the glucokinase gene of the fetus result in reduced birth weight. Nat. Genet. 19, 268-270 (1998).
67. Spyer G, Ballantyne E, Shepherd M et al.: Fetal growth is altered by fetal genotype and not insulin treatment of maternal hyperglycaemia in gestational diabetes due to mutations in the glucokinase gene. Diabet. Med. 17(Suppl.), A40 (2000).
68. Spyer G, Hattersley AT, Sykes JE, Sturley RH, MacLeod KM: Influence of maternal and fetal glucokinase mutations in gestational diabetes. Am. J. Obstet. Gynecol. 185, 240-241 (2001).
69. Njolstad P, Sovik O, Cuesta-Munoz A et al.: Neonatal diabetes mellitus due to complete glucokinase deficiency. N. Engl. J. Med. 344, 1588-1592 (2001).
70. Gloyn AL, Ellard S, Shield JP et al.: Complete glucokinase deficiency is not a common cause of permanent neonatal diabetes. Diabetologia 45, 290 (2002).
71. Vaxillaire M, Samson C, Cave H, Metz C, Froguel P, Polak M: Glucokinase gene mutations are not a common cause of permanent neonatal diabetes in France. Diabetologia 45, 454-455 (2002).
72. Njolstad PR, Sagen JV, Bjorkhaug L et al.: Permanent neonatal diabetes mellitus due to glucokinase deficiency - an inborn error of glucose-insulin signalling pathway. Diabetes 52, 2854-2860 (2003).
73. Porter JR, Shaw NJ, Barrett TG, Hattersley AT, Ellard S, Gloyn AL: Permanent neonatal diabetes in an Asian infant. J. Pediatr. 146, 131-133 (2005).
74. Garcia-Herrero CM, Galan M, Vincent O et al.: Functional analysis of human glucokinase gene mutations causing MODY2: exploring the regulatory mechanisms of glucokinase activity. Diabetalogia 50, 325-333 (2007).
75. Christesen HB, Jacobsen BB, Odili S et al.: The second activiting glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy. Diabetes 51, 1240-1246 (2002).
76. Gloyn AL, Noordam K, Willemsen MA et al.: Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. Diabetes 52, 2433-2440 (2003).
77. Cuesta-Munoz AL, Huopio H, Otonkoski T et al. Severe persistent hyperinsulinemic hypoglycemia due to de novo glucokinase mutation. Diabetes 53, 2164-2168 (2004).
78. Ashcroft FM, Harrison DE, Ashcroft SJ: Glucose induces closure of single potassium channels in isolated rat pancreatic β-cells: Nature 312, 446-448 (1984).
79. Ciement, JPI, Kunjilwar K, Gonzalez G. et al.: Association and stoichiometry of K-ATP channel subunits. Neuron 18, 827-838 (1997).
80. + channel. FEBS Lett. 409, 232-236 (1997).
81. Thomas PM, Cote GJ, Wohilk N et al.: Mutations in the sulphonylurea receptor and familial persistent hyperinsulinemic hypoglycemia of infancy. Science 268, 426-429 (1995).
82. Hattersley AT, Ashcroft FM: Activating mutations in kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 54, 2503-2513 (2005).
83. Tarasov AI, Welters HJ, Senkel S et al.: A Kir6.2 mutation causing neonatal diabetes impairs electrical activity and insulin secretion from INS-1 β-cells. Diabetes 55, 3075-3082 (2006).
84. Proks P, Girard C, Ashcroft FM: Functional effects of KCNJ11 mutations causing neonatal diabetes: enhanced activation by MgATP. Hum. Mol. Genet. 14, 2717-2726 (2005).
85. Proks P, Girard C, Haider S et al.: A gating mutation at the internal mouth of the Kir6.2 pore is associated with DEND syndrome. EMBO Rep. 6, 470-475 (2005).
86. Flanagan SE, Edghill EL, Gloyn AL, Ellard S, Hattersley AT. Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. Diabetologia 49 1190-1197 (2006).
87. Sakura H, Ammala C, Smith PA, Gribble FM, Ashcroft FM: Cloning and functional expression of the cDNA encoding a novel ATP-sensitive potassium channel subunit expressed In pancreatic β-cells, brain, heart and skeletal muscle. FEBS Lett. 377, 338-344 (1995).
88. Gloyn AL, Reimann F, Girard C et al.: Relapsing diabetes can result from moderately activating mutations in KCNJ11. Hum. Mol. Genet. 14, 925-934 (2005).
89. ATP channel and permanent neonatal diabetes: new insights and new treatment. Ann. Med. 37, 186-195 (2000).
90. Gloyn AL, Cummings EA, Edghill EL et al.: Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 gene encoding the Kir6.2 subunit of the β-cell potassium adenosine triphosphate channel. J. Clin. Endocrinol. Metab. 89, 3932-3935 (2004).
91. Edghin EL, Gloyn AL, Goriely A et al.: Origin of de novo KCNJ11 mutations and risk of neonatal diabetes for subsequent siblings. J. Clin. Endocrinol. Med. 92(5), 1773-1777 (2007).
92. Zlotogora, J: Germ line mosaicism. Hum. Genet. 102, 381-386 (1998).
93. Vaxillaire M, Dechaume A, Bustah K et al.: New ABCC8 mutations in relapsing neonatal diabetes and clinical features. Diabetest 56, 1737-1741 (2007).
94. Zung A, Glaser B, Nimri R, Zadik Z: Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J. Clin. Endocrinol. Metab. 89, 5504-5507 (2004).
95. Stanik J, Gasperikova D, Paskova M et al.: Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers. J. Clin. Endocrinol. Metab. 92, 1276-1282 (2007).
96. Proks P, Antcliff JF, Lippiat J, Gloyn AL, Hattersley AT, Ashcroft FM: Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proc. Natl Acad. Sci. USA 101, 17539-17544 (2004).
97. ATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) in diabetes mellitus and hyperinsulin. Hum. Mutat. 27, 220-231 (2006).
98. Nestorowicz A, Inagaki N, Gonot T et al.: A nonsense mutation in the inward rectifier potassium channel gene, Kir6.2 is assocaited with familial hyperinsulin. Diabetes 46, 1743-1748 (1997).
99. Verkarre V, Fournet JC, P de Lonlay et al.: Paternal mutation of the sulfonylurea receptor (SUR1) gene and maternal loss of 11p15 imprinted genes lead to persistent hyperinsulinism in focal adenomatous hyperplasia. J. Clin. Invest. 102, 1286-1291 (1998).
100. 18F-fluorodopa PET scan. J. Pediatr. 150, 140-145 (2007).
101. Suchi M, Thornton PS, Adzick NS et al.: Congenital hyperinsulinism: intraoperative biopsy interpretation can direct the extent of pancreatectomy. Am. J. Surg. Pathol. 28, 1326-1335 (2004).
102. Huopio H, Reimann F, Ashfield R et al.: Dominantly Inherited hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1. J. Clin. Invest. 106, 897-906 (2000).
103. Thornton PS, MacMullen C, Ganguly A et al.: Clinical and molecular characterization of a dominant form of congenital hyperinsulinism caused by a mutation in the high-affinity sulfonylurea receptor. Diabetes 52, 2403-2410 (2003).
104. Magge SN, Shyng SL, MacMullen C et al.: Familial leucine-sensitive hypoglycemia of infancy due to a dominant mutation of the β-cell suffonylurea receptor. J. Clin. Endocrinol. Metab. 89, 445-456 (2004).
105. Lin YW, MacMullen C, Ganguly A, Stanley CA, Shyng SL: A novel KCNJ11 mutation associated with congenital hyperinsulinism reduces the intrinsic open probability of β-cell ATP-sensitive potassium channels. J. Biol. Chem. 281, 3006-3012: (2006).
106. Huopio H, Otonkoski T, Vauhkonen I, Relmann F, Ashcroft F, Laakso M: A new subtype of autosomal dominant diabetes attributable to a mutation in the gene for the sulphonlyurea receptor 1. Lancet 361, 301-307 (2003).
107. Ræder H, Johansson S, Holm PI et al.: Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction. Nat. Genet. 38, 54-62 (2006).
108. Ræder H, Haldorsen IS. Ersland L et al.: pancreatic lipomatosis is a structural marker in nondiabetic children with mutations in carboxyl-ester lipase. Diabetes 56, 444-449 (2007).
109. Delepine M, Nicolino M, Barrett T, Golamaully M, Lathrop GM, Julier C: EIF2AK3, encoding translation initiation factor 2-α kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat. Genet. 25, 406-409 (2000).
110. Wildin RS, Ramsdell F, Peake J et al.: X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 27, 18-20 (2001).
111. Sellick GS, Barker KT, Stolte-Dijkstra I et al.: Mutations in PTF1A cause pancreatic and cerebellar agenesis. Nat. Genet. 36, 1301-1305 (2004).
112. Sesti G, Laratta E, Cardellini M et al.: The E23K variant of KCNJ11 encoding the pancreatic β-cell adenosine 5′ -triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. 91, 2334-2339 (2006).
113. Florez JC, Jablonski KA, Kahn SE, et al.: Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the diabetes prevention program. Diabetes 56, 531-536 (2007).
114. Wolford JK, Yeatts KA, Dhanjal SK et al.: Sequence variation in PPARG may underlie differential response to troglitazone. Diabetes 54, 3319-3325 (2005).
115. Florez JC, Jablonski KA, Bayley N et al.: TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N. Engl. J. Med. 355, 241-250 (2006).
116. Weedon MN, McCarthy MI, Hitman G et al.: Combining information from common Type 2 diabetes risk polymorphisms improves disease prediction. PLoS Med. 3, E374 (2006).
117. Sladek R, Rocheleau G, Rung J. et al.: A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445, 881-885 (2007).
118. Zeggini E, Weedon MN, Lindgren C et al.: Replication of genome-wide association signals in U.K. samples reveals risk loci for Type 2 diabetes. Science 316, 1336-1341 (2007).
119. Scott LJ. Mohlke KL, Bonnycastle LL et al.: A genome-wide association study of Type 2 diabetes in Finns detects multiple susceptibility variants. Science 316, 1341-1345 (2007).
120. Saxena R, Voight BF, Lyssenko V et al.: Genome-wide association analysis identifies loci for Type 2 diabetes and triglyceride levels. Science 316, 1331-1336 (2007).
121. Frayling TM, Timpson NJ, Weedon MN et al.: A common variant in the FTO gene is associated with body man index and predisposes to childhood and adult obesity. Science 316, 889-894 (2007).